CASBF (CanSino Biologics) Asset Impairment Charge: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASBF CanSino Biologics Inc CASBF
65 GF Score
Price $4.60
GF Value $9.20
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is CanSino Biologics Asset Impairment Charge?

CanSino Biologics CASBF 65 Asset Impairment Charge is $0.00 Mil as of Dec. 2025. GuruFocus rates CASBF with a GF Score™ of 65/100 and a GF Value™ of $9.20 (Significantly Undervalued). The stock has 2 warning signs investors should review.

CanSino Biologics's Asset Impairment Charge for the three months ended in Dec. 2025 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

CanSino Biologics Asset Impairment Charge Related Terms

CanSino Biologics Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for CanSino Biologics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanSino Biologics Asset Impairment Charge Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CanSino Biologics Quarterly Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Jun25 Sep25 Dec25 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CASBF
65GF Score
CanSino Biologics Inc CASBF
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CanSino Biologics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Asset Impairment Charge of $0.00 Mil mean?
CanSino Biologics (CASBF) has a Asset Impairment Charge of $0.00 Mil as of Dec. 2025.
Is CanSino Biologics' Asset Impairment Charge too high?
CanSino Biologics' current Asset Impairment Charge is $0.00 Mil. Overall, CanSino Biologics has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Asset Impairment Charge compare to ZTS?
CanSino Biologics' Asset Impairment Charge of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Drug Manufacturers company?
A good Asset Impairment Charge depends on the Drug Manufacturers industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. CanSino Biologics's current Asset Impairment Charge is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.20, compared to a current price of $4.60 — trading 50% below its estimated fair value. The current Asset Impairment Charge is $0.00 Mil. CanSino Biologics' overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Asset Impairment Charge is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CanSino Biologics (CASBF) Overvalued in 2026?

Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued. The current stock price of $4.60 is trading 50% below its estimated GF Value™ of $9.20. GuruFocus considers CanSino Biologics to be Significantly Undervalued.

Key valuation signals for CASBF:

  • Asset Impairment Charge: $0.00 Mil
  • GF Value™: $9.20 vs. price of $4.60 (50% below fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CanSino Biologics Business Description

Address 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
65GF Score

Get the complete analysis for CASBF

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price
$9.20
GF Value